Skip to main content
. 2016 Sep 6;3(7-8):258–265. doi: 10.18632/oncoscience.317

Figure 3. Kaplan-Meier estimates of survival for astrocytic tumor patients.

Figure 3

A. Patients with IDH1-R132H positive astrocytic tumors had a longer progressive-free survival than those with IDH1-R132H negative astrocytic tumors (p<0.0001). B. ATRX loss was also a favorable prognostic factor in patients with astrocytic tumors (p=0.0044). C. High Ki-67 expression was associated with shorter PFS in patients with astrocytic tumors (p=0.002). D. Survival analysis of the new classification revealed a remarkable separation of the clinical course in the three molecular subgroups (p<0.0001).